drugset / Trial / NCT03338010

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

NCT03338010

Phase 3 Completed 536 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.

Timeline

Start
2018-03-22
Primary completion
2020-03-18
Completion
2020-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2963016 Protein / enzyme biologic 10 iu Subcutaneous
Comparator insulin glargine Protein / enzyme biologic 10 iu Subcutaneous